Investigating Supply & Demand Side Factors of a Massive Covid-19 Vaccination Drive: Experimental Evidence from Indonesia


  • Indonesia is fighting one of the worst coronavirus outbreaks in Asia. On January 13, 2021, the country started one of the world’s biggest COVID-19 vaccination drives. The plan is to inoculate 181.5 million people – two third of the population – in 15 months using primarily the CoronaVac from China’s Sinovac Biotech. The vaccination campaign is ambitious and its success hinges on a number of supply and demand side factors which are subject to investigation in this project.
    DFG, 2021-2022


    Logo der Deutschen Forschungsgemeinschaft (DFG)

    Forschungsfragen

    We aim to look at two aspects in particular:

    1) On the demand-side, we aim to study in particular the role of religion for vaccine uptake.

    2) On the supply-side, we aim to study discrimination in access to health care and vaccination.

    Beitrag zu internationaler Forschung

    We aim at providing rigorous evidence on the role of religious beliefs for access to and demand of health services in the context of Indonesia. Beyond our scientific contribution, the findings are also of high policy relevance, not only in Indonesia but also for countries with substantial Muslim population shares and countries where discrimination in the access to health services is still endemic.

    Forschungsdesign und Methoden

    This study combines a standarized patient design with extensive survey evidence.


    GIGA Focus Global | 3/2022

    COVID-19 and Violent Actors in the Global South: A Complex Relationship

    Eine regional vergleichende Analyse der Auswirkungen von COVID-19 auf Gewalt zeigt eine beachtliche Varianz sowohl zwischen Kontexten als auch bewaffneten Akteuren. Während die Gewalt in Lateinamerika und dem Nahen Osten und Nordafrika insgesamt zurückging, stieg sie in Subsahara-Afrika an.

    Benachrichtigungen

    Melden Sie sich hier für E-Mail-Benachrichtigungen zu GIGA-Aktivitäten an

    Soziale Medien

    Folgen Sie uns